New
HealthMore in Health →
Review challenges core promise of anti-amyloid Alzheimer's drugs
A new review says anti-amyloid Alzheimer's treatments are unlikely to deliver clinically meaningful benefits and may raise the risk of brain bleeding and swelling, reopening debate over one of medicine's most contested R
Key Takeaways
- A new review says anti-amyloid Alzheimer's drugs likely do not provide clinically meaningful benefits.
- The same review says the drugs increase the risk of brain bleeding and swelling.
DE
DT Editorial AI··via medicalxpress.com